© 2023 BioMarin. All rights reserved.

A dynamic cross-section of business, clinical and biotechnical expertise with a proven track record of providing rapid access to breakthrough therapeutics.

Under the leadership of Chairman and Chief Executive Officer, Mr. Jean-Jacques Bienaimé, BioMarin’s executive management team includes accomplished leaders with deep and broad executive experience. Supported by a staff of approximately 3,000 employees worldwide, we are focused on delivering first-in-class and best-in-class therapeutics to patients with rare genetic diseases.

Our Pipeline

We maximize the impact of genetic innovation to develop transformative therapies.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

View Now Our Pipeline